dual agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
H2N-CO-NH2 → HNCO + NH3 H2N-CO-NH2 + HNCO → H2N-CO-NH-CO-NH2 H2N-CO-NH-CO-NH2 + HNCO → H2N-CO-NH-CO-NH-CO-NH2 As temperature exceeds 190 °C (374 °F), other reactions begin to dominate the process. The first appearance of ammeline occurs prior to 225 °C (437 °F) and is suspected also to occur from decomposition of biuret but is produced at a lower rate than that of CYA or ammelide.
Anemia Elevated creatine kinase (CPK) Elevated creatinine Elevated transaminases Hypercapnia Hypercholesterolemia (elevated LDL) Hyperlipidemia Hypoglycemia Hyponatremia Hypoxia Leukopenia Respiratory acidosis
== Proto-Hassuna == This period denotes a higher use of ceramics than with the pre-proto-Hassuna period. The site of Umm Dabaghiyah (de:Umm Dabaghiyah-Sotto-Kultur), in the same area of Iraq, is believed to have the earliest pottery in this region, and is sometimes described as a 'Proto-Hassuna culture' site. Other related sites in the area are Sotto and Yarim Tepe I, having 585 recorded ceramic fragments. They were found by archaeologist A.A. Bobrinsky. Another pre-Hassuna or proto-Hassuna site in Iraq is Tell Maghzaliyah. Yet another site with proto-Hassuna pottery is Ginnig. The time frame for this period was about 6700-6300 BC.
FAD-dependent proteins function in a large variety of metabolic pathways including electron transport, DNA repair, nucleotide biosynthesis, beta-oxidation of fatty acids, amino acid catabolism, as well as synthesis of other cofactors such as CoA, CoQ and heme groups. One well-known reaction is part of the citric acid cycle (also known as the TCA or Krebs cycle); succinate dehydrogenase (complex II in the electron transport chain) requires covalently bound FAD to catalyze the oxidation of succinate to fumarate by coupling it with the reduction of ubiquinone to ubiquinol. The high-energy electrons from this oxidation are stored momentarily by reducing FAD to FADH2. FADH2 then reverts to FAD, sending its two high-energy electrons through the electron transport chain; the energy in FADH2 is enough to produce 1.5 equivalents of ATP by oxidative phosphorylation. Some redox flavoproteins non-covalently bind to FAD like Acetyl-CoA-dehydrogenases which are involved in beta-oxidation of fatty acids and catabolism of amino acids like leucine (isovaleryl-CoA dehydrogenase), isoleucine, (short/branched-chain acyl-CoA dehydrogenase), valine (isobutyryl-CoA dehydrogenase), and lysine (glutaryl-CoA dehydrogenase). Additional examples of FAD-dependent enzymes that regulate metabolism are glycerol-3-phosphate dehydrogenase (triglyceride synthesis) and xanthine oxidase involved in purine nucleotide catabolism.
Sources: en.wikipedia.org
Materiel or matériel (; from French matériel 'equipment, hardware') is supplies, equipment, and weapons in military supply-chain management, and typically supplies and equipment in a commercial supply chain context.
== Good country == The Good Country Index seeks to measure every country's "contribution to the common good of humanity and the planet". Of 153 nations ranked in 2018, Thailand ranked 60 (1=best; 153=worst). Other ASEAN nations were ranked: Singapore, 23; Malaysia, 45; Philippines, 69; Brunei, 70; Indonesia, 87; Vietnam, 116; Cambodia, 130; Laos, 134. Myanmar was not included due to lack of data.
Emus flocked to the Chandler and Walgoolan area during a dry spell, damaging rabbit fencing and devastating crops. An attempt to drive them off was mounted, with the army called in to dispatch them with machine guns; the emus largely avoided the hunters. Emus are large, powerful birds, and their legs are among the strongest of any animal and powerful enough to tear down metal fencing. The birds are very defensive of their young, and there have been two documented cases of humans being attacked by emus.
=== Prader–Willi syndrome === Carbetocin was under development in an intranasal formulation for the treatment of Prader–Willi syndrome (PWS). It was variously developed by Ferring Pharmaceuticals, Levo Therapeutics, and Acadia Pharmaceuticals and had developmental code names including ACP-101, FE-992097, and LV-101. The drug reached and completed multiple phase 3 clinical trials for PWS prior to the discontinuation of its development in October 2025. It was discontinued due to lack of effectiveness.
a large increase in fake goods which are dangerous to health and safety; most products repossessed by authorities are now household items rather than luxury goods; a growing number of technological products; and, production is now operated on an industrial scale.
Sources: en.wikipedia.org
Betula alleghaniensis – yellow birch (B. lutea) (eastern Canada, Great Lakes, upper eastern US, Appalachians) Betula caerulea – blue birch (northeast of North America) Betula cordifolia – mountain paper birch (eastern Canada, Great Lakes, New England US) Betula glandulosa – American dwarf birch (Siberia, Mongolia, Russian Far East, Alaska, Canada, Greenland, mountains of western US and New England, Adirondacks) Betula kenaica – Kenai birch ( Alaska, northwestern North America) Betula lenta – sweet birch, cherry birch, or black birch (Quebec, Ontario, eastern US) Betula michauxii – Newfoundland dwarf birch (Newfoundland, Labrador, Quebec, Nova Scotia) Betula minor – dwarf white birch (eastern Canada, mountains of northern New England and Adirondacks) Betula murrayana – Murray's birch (Great Lakes endemic) Betula nana – dwarf birch or bog birch (also in northern Europe and Asia) Betula neoalaskana – Alaska paper birch also known as Alaska birch or Resin birch (Alaska and northern Canada) Betula nigra – river birch or black birch (eastern US) Betula occidentalis – water birch or red birch (B. fontinalis) (Alaska, Yukon, Northwest Territories, western Canada, western US) Betula papyrifera – paper birch, canoe birch or American white birch (Alaska, most of Canada, northern US) Betula populifolia – gray birch (eastern Canada, northeastern US) Betula pumila – swamp birch (Alaska, Canada, northern US) Betula uber – Virginia round-leaf birch (southwestern Virginia)
=== Industrial === Fatty acids are usually produced industrially by the hydrolysis of triglycerides, with the removal of glycerol (see oleochemicals). Phospholipids represent another source. Some fatty acids are produced synthetically by hydrocarboxylation of alkenes.
About one in ten marijuana users developed a substance use disorder, and those who use it before the age of 18 are more likely to suffer from it. Marijuana use in the United States is three times above the global average, but in line with other Western democracies. Forty-four percent of American high-school seniors have tried the drug at least once, and the typical age of first-use is 16, similar to the typical age of first-use for alcohol but lower than the first-use age for other illicit drugs.
==== Approved topical medicine ==== In the European Union, a prescription gel containing birch bark extract (commercial name Episalvan, betulae cortex dry extract (5–10 : 1); extraction solvent: n-heptane 95% (w/w)) was approved in 2016 for the topical treatment of minor skin wounds in adults. Although its mechanism of action in helping to heal injured skin is not fully understood, birch bark extract appears to stimulate the growth of keratinocytes which then fill the wound.
The four substrates of this enzyme are 3-hydroxyphenylacetic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are homogentisic acid, oxidised NAD+, and water. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 3-hydroxyphenylacetate,NAD(P)H:oxygen oxidoreductase (6-hydroxylating). This enzyme is also called 3-hydroxyphenylacetate 6-monooxygenase. It participates in styrene degradation.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.